Company Applied Therapeutics, Inc.

Equities

APLT

US03828A1016

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
6.8 USD -0.73% Intraday chart for Applied Therapeutics, Inc. -0.37% +102.99%

Business Summary

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.

Number of employees: 25

Sales per Business

USD in Million2022Weight2023Weight Delta
Biopharmaceutical
100.0 %
0 nan % 10 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 10 100.0 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 45 16-01-19
Director of Finance/CFO 55 16-05-31
Chief Operating Officer 57 Dec. 27
Chief Tech/Sci/R&D Officer 64 18-07-31
Comptroller/Controller/Auditor - 23-06-15
Corporate Officer/Principal 48 20-03-02

Members of the board

Members of the board TitleAgeSince
Director/Board Member 77 19-03-31
Director/Board Member 76 16-12-31
Director/Board Member 66 17-02-28
Director/Board Member 65 19-04-30
Director of Finance/CFO 55 16-05-31
Chief Executive Officer 45 16-01-19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 105,886,831 98,569,641 ( 93.09 %) 0 93.09 %

Shareholders

NameEquities%Valuation
Franklin Advisers, Inc.
9.087 %
7,017,912 9.087 % 50 M $
Janus Henderson Investors US LLC
8.306 %
6,414,642 8.306 % 46 M $
Alexandria Venture Investments LLC
8.234 %
6,359,054 8.234 % 45 M $
Venrock Associates
8.093 %
6,250,000 8.093 % 45 M $
Knoll Capital Management LP
7.089 %
5,474,687 7.089 % 39 M $
Propel Bio Management LLC
6.960 %
5,374,982 6.960 % 38 M $
5,316,580 6.884 % 38 M $
Vestal Point Capital LP
5.380 %
4,155,000 5.380 % 30 M $
Perceptive Advisors LLC
5.283 %
4,080,249 5.283 % 29 M $
Vanguard Global Advisers LLC
4.183 %
3,230,481 4.183 % 23 M $

Company contact information

Applied Therapeutics, Inc.

545 5th Avenue Suite 1400

10017, New York

+212 220 9226

http://www.appliedtherapeutics.com
address Applied Therapeutics, Inc.(APLT)